Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
“In people with NAFLD but without T2D, ameliorating NAFLD decreases T2D risk even after controlling for changes in weight (933).”
BackgroundInfluentialLack of Exercise Is a Major Cause of Chronic Diseases
Booth, F. W., Roberts, C. K., & Laye, M. J. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110025 · Cited by 2,575
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
New trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S.-U., & Wong, V. W.-S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,083
Stern, J. H., Rutkowski, J. M., & Scherer, P. E. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.011 · Cited by 1,031
“NAFLD and NASH are common in obesity, with up to 90% prevalence of NAFLD in the obese population (Bellentani et al., 2010).”
BackgroundBaeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609
Tang, A., Tan, J., Sun, M., Hamilton, G., Bydder, M., Wolfson, T., Gamst, A. C., Middleton, M., Brunt, E. M., Loomba, R., et al. (2013) · Radiology · doi:10.1148/radiol.12120896 · Cited by 528
Ertle, J., Dechêne, A., Sowa, J., Penndorf, V., Herzer, K., Kaiser, G., Schlaak, J. F., Gerken, G., Syn, W., & Canbay, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25797 · Cited by 518
“NASH occurs in about 3% of the adult population in the western world.(11,12)”
BackgroundNon-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal
Machado, M. V., & Cortez-Pinto, H. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.021 · Cited by 412
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
“For example, 80–90% of obese and 70–80% of T2DM patients typically have MAFLD [8,9].”
BackgroundOxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6776 · Cited by 386
“In childhood, the estimated prevalence of NAFLD in obese children is rising to 40–70% (18, 188).”
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
“5%-74%.(5,6) Each component of metabolic syndrome, such as central obesity, dyslipidemia, and hyperglycemia, is closely related to NAFLD.”
BackgroundTang, A., Desai, A., Hamilton, G., Wolfson, T., Gamst, A., Lam, J., Clark, L., Hooker, J., Chavez, T., Ang, B. D., et al. (2015) · Radiology · doi:10.1148/radiol.14140754 · Cited by 356
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2015) · Hepatology · doi:10.1002/hep.27678 · Cited by 354
Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity‐related Liver Disease
Vajro, P., Mandato, C., Licenziati, M. R., Franzese, A., Vitale, D. F., Lenta, S., Caropreso, M., Vallone, G., & Meli, R. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31821f9b85 · Cited by 341
The role of oxidative stress in non-alcoholic steatohepatitis
Koek, G. H., Liedorp, P. R., & Bast, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.013 · Cited by 314
Dietary Fructose and the Metabolic Syndrome
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Nutrients · doi:10.3390/nu11091987 · Cited by 295
Targher, G., & Byrne, C. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3093 · Cited by 297
Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents
Famouri, F., Shariat, Z., Hashemipour, M., Keikha, M., & Kelishadi, R. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001422 · Cited by 283
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173499 · Cited by 287
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsbøll, T., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188793 · Cited by 285
“The prevalence of ultrasonographic NAFLD in patients with T2D reaches 70% (Leite et al , 2009), much higher than the 25% of the general population with this diagnosis (Bellentani et al , 2010).”
The nutrition‐gut microbiome‐physiology axis and allergic diseases
McKenzie, C., Tan, J., Macia, L., & Mackay, C. R. (2017) · Immunological Reviews · doi:10.1111/imr.12556 · Cited by 270
Gu, J., Liu, S., Du, S., Zhang, Q., Xiao, J., Dong, Q., & Xin, Y. (2019) · European Radiology · doi:10.1007/s00330-019-06072-4 · Cited by 276
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Mikolasevic, I., Orlic, L., Franjic, N., Hauser, G., Stimac, D., & Milic, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7236 · Cited by 273
Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
Borrelli, A., Bonelli, P., Tuccillo, F. M., Goldfine, I. D., Evans, J. L., Buonaguro, F. M., & Mancini, A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.009 · Cited by 266
“NAFLD is present in 80–90% of obese individuals, in 30–50% of diabetics and approximately 90% of patients with hyperlipidemia [6].”
BackgroundInfluentialInsulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance
Petersen, M. C., Madiraju, A. K., Gassaway, B. M., Marcel, M., Nasiri, A. R., Butrico, G., Marcucci, M. J., Zhang, D., Abulizi, A., Zhang, X.-M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86013 · Cited by 240
“Though NAFLD is epidemiologically recognized as a risk factor for more severe clinical entities such as nonalcoholic steatohepatitis (40), hepatocellular carcinoma (40), and T2D (41), most individuals with NAFLD — an estimated 30% of Americans (1) — are undiagnosed (42), and there is ample conflicting evidence regardi…”
BackgroundInfluentialGut microbiota and non-alcoholic fatty liver disease: new insights
Aron-Wisnewsky, J., Gaborit, B., Dutour, A., & Clement, K. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12140 · Cited by 248
Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism
Sinha, R. A., Singh, B. K., & Yen, P. M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.07.001 · Cited by 241
Nabavi, S., Rafraf, M., Somi, M. H., Homayouni-Rad, A., & Asghari-Jafarabadi, M. (2014) · Journal of Dairy Science · doi:10.3168/jds.2014-8500 · Cited by 235
“The prevalence of this disorder in general population screening with ultrasonography is reported to be 20 to 30% (Bellentani et al., 2010).”
BackgroundFatty Acid–Regulated Transcription Factors in the Liver
Jump, D. B., Tripathy, S., & Depner, C. M. (2013) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161139 · Cited by 228
“NAFLD is now the most common cause of liver disease in developed countries (7) and is defined as excessive lipid accumulation in the liver, i.”
BackgroundChen, S., Zhao, X., Wan, J., Ran, L., Qin, Y., Wang, X., Gao, Y., Shu, F., Zhang, Y., Liu, P., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.009 · Cited by 235
Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease
Lake, A. D., Novak, P., Shipkova, P., Aranibar, N., Robertson, D. G., Reily, M. D., Lehman-McKeeman, L. D., Vaillancourt, R. R., & Cherrington, N. J. (2015) · Amino Acids · doi:10.1007/s00726-014-1894-9 · Cited by 232
“The incidence of NAFLD in many countries is similar to the 30–40 % prevalence estimates of NAFLD in the United States population (Ali and Cusi 2009; Bellentani et al. 2010; Koehler et al. 2012; Wong et al. 2012).”
Machado, M. V., Oliveira, A. G., & Cortez‐Pinto, H. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06801.x · Cited by 233
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
Flemming, J. A., Kim, W. R., Brosgart, C. L., & Terrault, N. A. (2017) · Hepatology · doi:10.1002/hep.28923 · Cited by 231
“However, this increase in median age was most pronounced in the HCV population increasing from 53 years in 2003 to 57 years (IQR, 52-61) in 2015.”
BackgroundInfluentialBortolin, R. C., Vargas, A. R., Gasparotto, J., Chaves, P. R., Schnorr, C. E., Martinello, K. B., Silveira, A. K., Rabelo, T. K., Gelain, D. P., & Moreira, J. C. F. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.225 · Cited by 221
Afericoes e exames clinicos realizados nos participantes do ELSA-Brasil
Mill, J. G., Pinto, K., Griep, R. H., Goulart, A., Foppa, M., Lotufo, P. A., Maestri, M. K., Ribeiro, A. L., Andreao, R. V., Dantas, E. M., et al. (2013) · Revista de Saúde Pública · doi:10.1590/s0034-8910.2013047003851 · Cited by 220
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
Glen, J., Floros, L., Day, C., & Pryke, R. (2016) · BMJ · doi:10.1136/bmj.i4428 · Cited by 213
Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., de Araujo Horcel, L., Pinatel, E. M., Alisi, A., Nobili, V., & Feldstein, A. E. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.07.007 · Cited by 221
“NAFLD has grown to become the most common chronic liver disease in both adults and children.(40,41) The early stages of the disease are characterized by the overaccumulation of fat mainly in the form of triglycerides in the liver resulting in hepatic steatosis.”
BackgroundZimmermann, E., Gamborg, M., Holst, C., Baker, J. L., Sørensen, T. I. A., & Berentzen, T. L. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006998 · Cited by 213
“NAFLD is often associated with insulin resistance and other metabolic alterations, and is considered the hepatic manifestation of the metabolic syndrome.(7) In the Western world, NAFLD is now the most frequent form of chronic liver disease in children and adults.”
BackgroundFailure Rates in the Hepatocellular Carcinoma Surveillance Process
Singal, A. G., Yopp, A. C., Gupta, S., Skinner, C. S., Halm, E. A., Okolo, E., Nehra, M., Lee, W. M., Marrero, J. A., & Tiro, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0046 · Cited by 208
Li, Z., Xue, J., Chen, P., Chen, L., Yan, S., & Liu, L. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12428 · Cited by 202
Milić, S., & Štimac, D. (2012) · Digestive Diseases · doi:10.1159/000336669 · Cited by 192
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
“Nonalcoholic fatty liver disease (NAFLD) and its progressed inflammatory state [nonalcoholic steatohepatitis (NASH)] are manifestations of metabolic syndrome in the liver and have emerged as leading causes of abnormal liver function (6).”
BackgroundPrediction, prevention and management of postresection liver failure
Hammond, J. S., Guha, I. N., Beckingham, I. J., & Lobo, D. N. (2011) · British Journal of Surgery · doi:10.1002/bjs.7630 · Cited by 187
Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
Tana, C., Ballestri, S., Ricci, F., Di Vincenzo, A., Ticinesi, A., Gallina, S., Giamberardino, M. A., Cipollone, F., Sutton, R., Vettor, R., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16173104 · Cited by 191
“In fact, NAFLD prevalence ranges from 50%–75% in subjects with type 2 diabetes [7,8], and, according to different studies, from 80%–90% in obese subjects [9,10].”
BackgroundNewsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds
Xu, C., Wan, X., Xu, L., Weng, H., Yan, M., Miao, M., Sun, Y., Xu, G., Dooley, S., Li, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.019 · Cited by 186
Fernando, D. H., Forbes, J. M., Angus, P. W., & Herath, C. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205037 · Cited by 184
“For example, the prevalence in the USA is 33.6% among the adult population and 10–20% in children, whereas it is 25% in Europe [1], 25% in Asia [2] and 30% among adults in Australia (GESA, 2012).”
BackgroundInfluentialGlobal Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations
Sherif, Z. A., Saeed, A., Ghavimi, S., Nouraie, S.-M., Laiyemo, A. O., Brim, H., & Ashktorab, H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4143-0 · Cited by 179
The prevalence of nonalcoholic fatty liver disease in the Americas
López-Velázquez, J. A., Silva-Vidal, K. V., Ponciano-Rodríguez, G., Chávez-Tapia, N. C., Arrese, M., Uribe, M., & Méndez-Sánchez, N. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30879-8 · Cited by 178
Diets and nonalcoholic fatty liver disease: The good and the bad
Asrih, M., & Jornayvaz, F. R. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2013.11.003 · Cited by 175
Sex-dimorphic and age-dependent organization of 24-hour gene expression rhythms in humans
Talamanca, L., Gobet, C., & Naef, F. (2023) · Science · doi:10.1126/science.add0846 · Cited by 169
Patel, N. S., Doycheva, I., Peterson, M. R., Hooker, J., Kisselva, T., Schnabl, B., Seki, E., Sirlin, C. B., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.039 · Cited by 173
Mayo, R., Crespo, J., Martínez‐Arranz, I., Banales, J. M., Arias, M., Mincholé, I., Aller de la Fuente, R., Jimenez‐Agüero, R., Alonso, C., de Luis, D. A., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1188 · Cited by 164
“Following assessment, patients were classified by the pathologists into the following three histologic groups: (1) NL, (2) NAFL (hepatic steatosis alone), and (3) NASH (presence as determined by the pathologist).”
BackgroundMethodInfluentialWhat about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?
Tarantino, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i22.3375 · Cited by 166
Li, J., Huang, J., Li, J.-S., Chen, H., Huang, K., & Zheng, L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.018 · Cited by 168
Shabalala, S. C., Dludla, P. V., Mabasa, L., Kappo, A. P., Basson, A. K., Pheiffer, C., & Johnson, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110785 · Cited by 178
SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
Colak, Y., Ozturk, O., Senates, E., Tuncer, I., Yorulmaz, E., Adali, G., Doganay, L., & Enc, F. Y. (2011) · Medical Science Monitor · doi:10.12659/msm.881749 · Cited by 165
“Within the spectrum of NAFLD, only nonalcoholic steatohepatitis (NASH) has been convincingly shown to have a progressive course.”
BackgroundInfluentialLake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki, W. T., & Cherrington, N. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040592 · Cited by 167
“Globally, the prevalence of NAFLD is expected to approach that of the United States because of the spread of western lifestyle (Bellentani et al., 2010).”
BackgroundNon-alcoholic Fatty Liver Disease: A Clinical Update
Pappachan, J. M., Babu, S., Krishnan, B., & Ravindran, N. C. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00013 · Cited by 154
“Prevalence of NAFLD also increases with age (up to 46%), with the older age groups having higher mortality rates.(9,10)”
BackgroundBurra, P., Bizzaro, D., Gonta, A., Shalaby, S., Gambato, M., Morelli, M. C., Trapani, S., Floreani, A., Marra, F., Brunetto, M. R., et al. (2021) · Liver International · doi:10.1111/liv.14943 · Cited by 162
Obesity, insulin resistance, NASH and hepatocellular carcinoma
Yu, J., Shen, J., Sun, T. T., Zhang, X., & Wong, N. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.07.003 · Cited by 161
Ullah, R., Rauf, N., Nabi, G., Ullah, H., Shen, Y., Zhou, Y., & Fu, J. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30121 · Cited by 172
“The prevalence of NAFLD in children is 3% but it increases up to 50%-70% among obese children [4].”
BackgroundModerate alcohol use and health: A consensus document
Poli, A., Marangoni, F., Avogaro, A., Barba, G., Bellentani, S., Bucci, M., Cambieri, R., Catapano, A. L., Costanzo, S., Cricelli, C. A., et al. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.02.007 · Cited by 179
Self-citationPark, H.-S., Jang, J. E., Ko, M. S., Woo, S. H., Kim, B. J., Kim, H. S., Park, H. S., Park, I.-S., Koh, E. H., & Lee, K.-U. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.376 · Cited by 160
“NAFLD is the most common cause of chronic liver disease in developed countries [4], and the prevalence in the general population ranges from 20% to 30% [5].”
BackgroundKhan, H., Ullah, H., & Nabavi, S. M. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.12.002 · Cited by 156
Gopal, P., Yopp, A. C., Waljee, A. K., Chiang, J., Nehra, M., Kandunoori, P., & Singal, A. G. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.053 · Cited by 157
“The higher accuracy of AFP for detecting HCC among patients without HCV infection is particularly important given the rising incidence of NASH in the United States and Europe.”
BackgroundInfluentialFukuda, T., Hamaguchi, M., Kojima, T., Hashimoto, Y., Ohbora, A., Kato, T., Nakamura, N., & Fukui, M. (2016) · Liver International · doi:10.1111/liv.12912 · Cited by 157
Estrogen as a key regulator of energy homeostasis and metabolic health
Mahboobifard, F., Pourgholami, M. H., Jorjani, M., Dargahi, L., Amiri, M., Sadeghi, S., & Tehrani, F. R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113808 · Cited by 154
Trak-Smayra, V., Paradis, V., Massart, J., Nasser, S., Jebara, V., & Fromenty, B. (2011) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2011.00793.x · Cited by 146
“Hence, although ob ⁄ ob and db ⁄ db mice do not display the whole spectrum of human NASH, these obese animals could represent a suitable model to study NAFLD as the majority of obese and diabetic individuals develop simple steatosis without major necroinflammation or extensive fibrosis (Bellentani et al. 2010; Schatte…”
BackgroundGraffy, P. M., Sandfort, V., Summers, R. M., & Pickhardt, P. J. (2019) · Radiology · doi:10.1148/radiol.2019190512 · Cited by 145
Hafeez, S., & Ahmed, M. H. (2013) · Journal of Obesity · doi:10.1155/2013/839275 · Cited by 144
“Antiobesitymedications such as Orlistat [53] and drugs that augment insulin sensitivity and reduce plasma glucose concentrations and oxidative stress such asiazolidinediones [54] andMetformin [52] are amongst those shown to improve liver histology in NAFLD.”
BackgroundSchlesinger, S., Aleksandrova, K., Pischon, T., Jenab, M., Fedirko, V., Trépo, E., Overvad, K., Roswall, N., Tjønneland, A. M., Boutron‐Ruault, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt204 · Cited by 149
“In accordance, it has been shown that diabetes is related with a spectrum of obesitydriven liver diseases [27], which are associated with hepatocyte injury, inflammation, and fibrosis and are presumably risk factors for HCC [8].”
BackgroundLiu, J., Han, L., Zhu, L., & Yu, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0194-7 · Cited by 145
Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)
Alwahsh, S. M., & Gebhardt, R. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1892-7 · Cited by 148
Tosello‐Trampont, A., Krueger, P., Narayanan, S., Landes, S. G., Leitinger, N., & Hahn, Y. S. (2016) · Hepatology · doi:10.1002/hep.28389 · Cited by 142
“Prevalence of NAFLD is estimated to be 30% of the population in Western countries.((37)) Although NASH contributes to only 2%-3% of this figure, it poses a significant health burden, because it is the precursor to fibrosis and cirrhosis of the liver.”
BackgroundOmega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
“NAFLD is the most common chronic fatty liver disease in developed countries (Bellentani et al., 2010); and is strongly associated with obesity (Cohen et al., 2011; Farrell, 2006; LaubySecretan, 2016).”
BackgroundCOVID‐19 and non‐alcoholic fatty liver disease: Two intersecting pandemics
Portincasa, P., Krawczyk, M. J., Smyk, W., Lammert, F., & Ciaula, A. D. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13338 · Cited by 146
Epigenetics in non-alcoholic fatty liver disease
Lee, J.-H., Kim, Y., Friso, S., & Choi, S. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.11.008 · Cited by 152
Kurek, K., Piotrowska, D. M., Wiesiołek‐Kurek, P., Łukaszuk, B., Chabowski, A., Górski, J., & Żendzian‐Piotrowska, M. (2014) · Liver International · doi:10.1111/liv.12331 · Cited by 132
“The prevalence of nonalcoholic fatty liver disease in general population has been estimated to range from 20% to almost 50% (27, 28) and it grows dramatically up to 80–90% in obese adults and in patients with hyperlipidaemia (29).”
BackgroundCost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
O'Hara, J., Finnegan, A., Dhillon, H., Ruiz-Casas, L., Pedra, G., Franks, B., Morgan, G., Hebditch, V., Jönsson, B., Mabhala, M., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100142 · Cited by 129
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., & Wakabayashi, G. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00164 · Cited by 133
Ou, Q., Weng, Y., Wang, S., Zhao, Y.-J., Zhang, F., Zhou, J., & Wu, X. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5268-0 · Cited by 133
The complement system in human cardiometabolic disease
Hertle, E., Stehouwer, C. D. A., & van Greevenbroek, M. M. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.031 · Cited by 137
“Also MBL genotypes, hich are commonly used as proxy of MBL plasma concentrations, ere not associated with presence of NAFLD (Rensen et al., 2009). he only study on the alternative pathway did not observe FD to e elevated in patients with biopsy proven NAFLD (Yilmaz et al., 011).”
BackgroundInfluentialKalra, S., Vithalani, M., Gulati, G., Kulkarni, C. M., Kadam, Y., Pallivathukkal, J. K., Das, B., Sahay, R. K., & Modi, K. D. (2013) · PubMed · Cited by 131
Miller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
“Moreover, MASH, the progressive form of MASLD, is recognised as one of the leading indications for liver transplantation globally, accounting for ~20.3% of all transplants in Western countries, ri-valling hepatitis C and alcohol-related liver disease [35, 39].”
InfluentialPatel, N. S., Peterson, M. R., Brenner, D. A., Heba, E., Sirlin, C., & Loomba, R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12237 · Cited by 127
Systematic review with meta‐analysis: coffee consumption and the risk of cirrhosis
Kennedy, O. J., Roderick, P., Buchanan, R., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13523 · Cited by 125
Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
Simón, J., Ouro, A., Ala-Ibanibo, L., Presa, N., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010040 · Cited by 134
“This condition is particularly manifested in Western countries, with an incidence rate of about 20%–30% in the general population [1,2].”
BackgroundFXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Carr, R. M., & Reid, A. E. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0500-2 · Cited by 132
“FXR and SREBP1 Sterol regulatory element-binding transcription factor 1 (SREBP1) is a nuclear transcription factor important for de novo lipogenesis, a process upregulated in NASH patients and NAFLD experimental models that results in the synthesis of lipids [47].”
BackgroundInfluentialLeite, N. C., Villela-Nogueira, C. A., Cardoso, C. R. L., & Salles, G. F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8377 · Cited by 142
Epigenetic Mechanisms Underlying the Link between Non-Alcoholic Fatty Liver Diseases and Nutrition
Lee, J., Friso, S., & Choi, S.-W. (2014) · Nutrients · doi:10.3390/nu6083303 · Cited by 121
“The prevalence of NAFLD in the general population of Western countries ranges from 20% to 30% [10,11].”
BackgroundMouzaki, M., & Allard, J. P. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31824cf51e · Cited by 122
Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.073 · Cited by 123
Developmental Origins of Health and Disease – from a small body size at birth to epigenetics
Eriksson, J. G. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1193786 · Cited by 115
“Non-alcoholic fatty liver disease (NAFLD), defined by a liver fat content exceeding 5–10% has a prevalence of 20–30% in Western societies, is one of the most common causes of chronic liver disease (40,41).”
Background
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.